Full-Time

Associate Director

Global Real-World Evidence, Oncology

Posted on 8/5/2026

Deadline 8/23/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$137k - $235.8k/yr

+ Long-term incentive program

Raritan, NJ, USA

Hybrid

Hybrid work is required in Raritan, New Jersey; approximately 10% travel is required, primarily domestic with some international travel.

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Python
SAS
Data Visualization
Data Science
R
Electronic Health Records (EHR)
Biostatistics
Data Analysis

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • An advanced degree in epidemiology, pharmacoepidemiology, health economics and outcomes research, public health, biostatistics, health policy, health services research, or a related field is required.
  • A minimum of 5 years of relevant experience in the pharmaceutical, biotechnology, consulting, academic, or healthcare environment is required, with experience in real-world evidence, epidemiology, outcomes research, medical affairs, market access, or related functions.
  • Demonstrated experience supporting the design and execution of real-world evidence studies, including observational studies, retrospective database analyses, evidence synthesis, protocol development, analytic planning, interpretation of results, and scientific dissemination.
  • Strong working knowledge of real-world data sources and fit-for-purpose real-world evidence methods is required, including claims databases, electronic health records, registries, chart reviews, and other healthcare data sources.
  • Ability to provide methodological input on observational study design, analytic approaches, bias mitigation, data interpretation, and communication of real-world evidence findings to technical and non-technical audiences is required.
  • Experience collaborating with programmers, statisticians, epidemiologists, real-world evidence researchers, cross-functional partners, and external vendors to execute data-driven research projects is required.
  • Strong project management skills are required, including the ability to manage timelines, coordinate deliverables, track decisions and actions, support governance processes, and drive execution in a matrixed global environment.
  • Strong communication, presentation, and scientific writing skills are required, with the ability to translate complex research concepts and data-driven insights into clear messages for internal and external stakeholders.
  • Experience contributing to publications, congress presentations, internal evidence-generation deliverables, or other scientific communication outputs is required.
Responsibilities
  • Support the Global Real-World Evidence Disease Lead in developing and maintaining Integrated Evidence Generation Plans and long-range Worldwide Real-World Evidence Roadmaps for assigned disease areas and assets.
  • Drive high-quality execution of priority real-world evidence studies and evidence-generation projects, ensuring timely delivery, scientific rigor, operational excellence, and appropriate interpretation and dissemination of study outputs.
  • Collaborate with real-world evidence researchers, programmers, cross-functional partners, regional and local evidence-generation teams, and external vendors to translate study concepts into protocols, analyses, deliverables, publications, and other evidence-dissemination materials.
  • Support the Disease Lead in global and regional stakeholder management across cross-functional workstreams, real-world evidence working groups, Evidence Labs, and project execution forums.
  • Serve as a methodology subject matter expert in assigned cross-functional workstreams, providing scientific input on real-world data sources, observational study designs, analytic approaches, fit-for-purpose evidence methods, and best practices.
  • Analyze, interpret, and synthesize real-world data, literature, competitive evidence, and stakeholder insights to inform evidence-gap assessments, strategic trade-off discussions, urgent business requests, and cross-functional decision-making.
  • Contribute to real-world evidence operational governance, standards, processes, and operating models by supporting prioritization, resource planning, deliverable tracking, review processes, vendor oversight, and consistency across disease- and asset-level activities.
  • Ensure assigned real-world evidence activities comply with applicable regulatory, legal, privacy, publication, and commercial requirements while upholding scientific integrity, responsible communication, and evidence dissemination.
Desired Qualifications
  • A PhD is preferred.
  • Experience with global, multi-country real-world evidence studies is preferred.
  • Hands-on experience with SAS, R, Python, or other statistical programming tools is preferred.
  • Oncology experience is strongly preferred.
  • Working knowledge of the global healthcare, reimbursement, payer, medical affairs, and evidence-generation environment is preferred, particularly as it relates to oncology product strategy and stakeholder evidence needs.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales hit $25.3 billion, and guidance rose to $101.1 billion.
  • TREMFYA, INLEXZO, and ICOTYDE are accelerating, offsetting STELARA's 55% quarterly collapse.
  • FDA-cleared OTTAVA begins US commercialization, expanding J&J's robotic surgery platform this year.

What critics are saying

  • The July 2026 talc settlement leaves future claims unresolved and UK litigation active.
  • STELARA biosimilars and Imbruvica competition keep eroding legacy pharma cash flows in 2026.
  • Abiomed weakened after the UK Impella study, and PROTECT IV data arrives in 2027.

What makes Johnson & Johnson unique

  • J&J spans pharmaceuticals, MedTech, and consumer brands across entrenched hospital workflows.
  • Its scale funds constant launches, from TREMFYA to OTTAVA, across multiple therapies.
  • Deep surgeon and hospital switching costs protect MedTech franchises like da Vinci-adjacent competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 4th, 2026
JNJ returns $85B to shareholders but stock still lags S&P 500 by 13%

Johnson & Johnson returned $85 billion to shareholders over the past five years through $60 billion in dividends and $25 billion in share buybacks, equivalent to 13.8% of its current market capitalisation. The healthcare giant generated $97.93 billion in revenue over the last twelve months with a 27% operating margin. Despite this substantial cash return, JNJ shareholders saw a total return of 70% over five years, underperforming the S&P 500's 83% return. The company's Innovative Medicine division showed strong performance, with double-digit growth excluding STELARA and successful launches like ICOTYDE. However, the MedTech segment struggled, particularly in cardiovascular, where the Abiomed heart pump business saw sales decline 2%. The performance gap between divisions raises questions about whether returning cash signals disciplined capital allocation or a shortage of high-return growth opportunities.

Yahoo Finance
Jul 31st, 2026
J&J beats estimates with $25.3B revenue, raises guidance to $101.1B for the year

Johnson & Johnson reported strong Q2 2026 results with sales rising nearly 7% to $25.31 billion, beating estimates of $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expected $2.85. The company raised its full-year guidance and remains on track to exceed $100 billion in annual revenue for the first time in its 140-year history. Its pharmaceutical division generated $16.38 billion in quarterly sales. Despite a 55% drop in Stelara revenue to $740 million due to patent loss, newer drugs compensated for the decline. Tremfya sales surged 72.5% to $2 billion, well above the $1.74 billion estimate. Meanwhile, Danaher delivered encouraging Q2 results driven by its Life Sciences business, with bioprocessing orders growing mid-teens despite timing-related revenue fluctuations.

Yahoo Finance
Jul 28th, 2026
J&J to pay $5.5B to settle 76,000 talc baby powder cancer lawsuits

Johnson & Johnson has agreed to pay $5.5 billion to settle approximately 76,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. The settlement requires acceptance by at least 95% of claimants to take effect. The company expects to make an initial payment of no more than $3 billion in 2027, with additional payments due from 2028. Legal representatives suggest the total payout could reach $7 billion or more. The deal is designed to deliver payment to all claimants within 18 months and covers only current claims, leaving future lawsuits outside its scope. J&J maintains the claims lack merit but said the settlement allows it to move forward. The agreement follows three years of halted proceedings whilst J&J pursued unsuccessful bankruptcy strategies through a subsidiary. The company withdrew its talc-based baby powder from US shelves in 2020 and worldwide in 2023.

Yahoo Finance
Jul 27th, 2026
J&J's MedTech sales rise 4.5% to $8.93B in Q2 amid Abiomed weakness and electrophysiology pressure

Johnson & Johnson's MedTech segment delivered mixed second-quarter 2026 results. Sales rose 4.5% to $8.93 billion but missed the consensus estimate of $8.96 billion. The shortfall stemmed from weaker cardiovascular performance, particularly in Abiomed, where sales declined 2% due to slow procedural volumes for the Impella heart pump. Physician uncertainty following a UK study questioning Impella's benefit in certain high-risk procedures contributed to reduced usage. Despite cardiovascular weakness, J&J's Surgery, Vision, and Orthopedics businesses accelerated above expectations, growing 3.9%, 6.0%, and 4.9% respectively. Shockwave revenues rose 14.6% to $335 million. J&J characterised the Abiomed issue as temporary and noted stable overall procedure volumes across its MedTech business, with no meaningful impact from expired Affordable Care Act subsidies.

Yahoo Finance
Jul 27th, 2026
J&J exec sells $5.8M in shares as stock climbs 27% despite biosimilar and competition headwinds

Johnson & Johnson executive Vanessa Broadhurst sold 23,054 shares worth approximately $5.8 million on 20 July, representing about half her stake. The stock has risen 27% this year. J&J has restructured through recent spin-offs of its consumer health and orthopaedics units to focus on higher-growth areas. Management targets 6% operational sales growth for 2026, aiming for double-digit growth by decade's end. Recent quarterly revenue increased 6.6% year-over-year, with oncology up 17.3%. Darzalex grew nearly 18%, whilst Tremfya surged 72.5%. Management raised full-year earnings guidance. However, older blockbuster Stelara declined due to biosimilar competition, and Imbruvica dropped 18.5% on competitive pressure. The stock trades at roughly 21-22 times forward earnings, about 10% above sector median, with a 2.2% dividend yield.